Scientists call regulatory T cells the immune system’s “peacekeepers.” These special cells calm overactive immune responses. Moreover, they prevent the body from attacking itself in autoimmune diseases.
Researchers now develop Treg therapies to harness this power. They expand or engineer these cells. Then, they infuse them back into patients. This approach restores balance without broad suppression.
Clinical trials advance quickly. Over 70 studies test Treg treatments worldwide. Many target autoimmune conditions like type 1 diabetes, rheumatoid arthritis, and lupus. Additionally, trials prevent graft-versus-host disease after transplants.
Low-dose IL-2 stimulates natural Tregs. This method boosts Treg numbers safely. For example, rezpegaldesleukin shows strong results in atopic dermatitis. It promotes Treg growth and reduces inflammation effectively.
Adoptive Treg transfer gains momentum. Doctors extract patients’ Tregs, multiply them in labs, and reinfuse them. Polyclonal Tregs lead most trials. Engineered versions, like CAR-Tregs, emerge next. These target specific tissues precisely.
CAR-Treg therapies show early promise. Companies engineer Tregs with chimeric antigen receptors. Trials focus on transplant rejection and autoimmune flares. Thus, they offer targeted tolerance without harming overall immunity.
Breakthroughs address key challenges. New protocols expand Tregs before transplants. This reduces GVHD risk while preserving anti-cancer effects. Furthermore, epigenetic reprogramming creates stable, potent Tregs.
The field explodes with innovation. The 2025 Nobel Prize spotlighted Treg discovery. Now, biotech firms race forward. Partnerships accelerate manufacturing and trials.
Overall, Treg therapies represent a game-changer. They shift from suppression to true immune tolerance. Patients await safer, more precise options soon. Stay tuned—the peacekeepers arrive.